2-lithioquinoline | 75164-10-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-lithioquinoline
• 英文别名: 2-quinolyllithium；[2]quinolyl lithium；[2]Chinolyllithium；2-quinolyl lithium
• CAS: 75164-10-2
• 化学式: C₉H₆LiN
• 分子量: 135.094
• InChiKey: QEQCOWQQZBOKHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.03
• 重原子数：
  11.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.89
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  2-lithioquinoline 在 ClAgAsPh₃ 作用下， 生成 2,2'-联喹啉
  参考文献：
  名称：

  有机金化学：IV。喹啉基和菲啶基金（I）化合物

  摘要：

  DOI：

  10.1016/s0022-328x(00)85924-0
• 作为产物：
  描述：

  2-溴喹啉 、 正丁基锂 在 四氢呋喃 作用下， 生成 2-lithioquinoline
  参考文献：
  名称：

  Notes - Carbonation of Lithium Derivatives of Certain Quinolines and Isoquinolines

  摘要：

  DOI：

  10.1021/jo01356a605

文献信息

• Amino pyridine derivatives
  申请人：John Wyeth & Brother Limited

  公开号：US04180670A1

  公开（公告）日：1979-12-25

  Novel 4-pyridinamine derivatives having the formula ##STR1## [where R.sup.1 and R.sup.2 are aryl or heteroaryl (optionally linked together by a lower alkylene bridge) or one of R.sup.1 and R.sup.2 is aryl or heteroaryl and the other of R.sup.1 and R.sup.2 is lower alkyl or ar(lower)alkyl, R.sup.3 and R.sup.4 are each hydrogen or lower alkyl and n is 0 or 1] and their non-toxic acid addition salts are described. They show CNS activity and may be used as antidepressant drugs. Some also show stimulant activity. Novel intermediates having the formula ##STR2## are also described.

  描述了具有以下结构的新型4-吡啶胺衍生物 [其中R.sup.1和R.sup.2是芳基或杂环芳基（可选择通过较低的烷基桥连接在一起），或者R.sup.1和R.sup.2中的一个是芳基或杂环芳基，另一个是较低烷基或芳基（较低）烷基，R.sup.3和R.sup.4分别是氢或较低烷基，n为0或1]，以及它们的无毒酸盐。它们显示中枢神经系统活性，可用作抗抑郁药物。其中一些还显示兴奋活性。还描述了具有以下结构的新型中间体。
• Method for Producing Fluorine-Containing Substituted Compound and Fluorine-Containing Substituted Compound
  申请人：Taiyo Nippon Sanso Corporation

  公开号：US20140012027A1

  公开（公告）日：2014-01-09

  A method for producing a fluorine-containing substituted compound, the method including: introducing an organofluorine compound and an organolithium compound into a microreactor provided with a flow path capable of mixing a plurality of liquids, to thereby obtain a reaction product; and introducing, into the microreactor, the reaction product and an electrophile exhibiting electrophilic effect on the reaction product, to thereby obtain a fluorine-containing substituted compound.

  一种制备含氟取代化合物的方法，包括：将有机氟化合物和有机锂化合物引入具有混合多种液体的流动路径的微反应器中，从而获得反应产物；并将反应产物和对反应产物具有亲电效应的电子亲和体引入微反应器中，从而获得含氟取代化合物。
• Methanoanthraceneyl methyl piperidinyl compounds
  申请人：Zeneca Limited

  公开号：US05512575A1

  公开（公告）日：1996-04-30

  Compounds of formula I or I', ##STR1## wherein X and Y are independently selected from hydrogen, halo, and (1-6C)alkoxy; R.sup.1 is selected from (A) (1-6C)alkyl; (B) phenyl and naphthyl or substituted versions thereof; (C) phenyl (1-3C)alkyl and naphthyl (1-3C) alkyl; (D) five- and six-membered heteroaryl rings; (E) heteroaryl (1-3C)alkyl and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disorders such as psychoses; pharmaceutical compositions comprising a compound of formula I or I' and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropsychiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective amount of a compound of formula I or I', or a pharmaceutically acceptable salt thereof are claimed. The invention also relates to novel processes for producing enantiomeric methanoanthracenyl sulfoxides.

  公式I或I'的化合物，其中X和Y分别选自氢，卤素和（1-6C）烷氧基; R1从以下选出：（A）（1-6C）烷基; （B）苯和萘或其取代物; （C）苯（1-3C）烷基和萘（1-3C）烷基; （D）五元和六元杂环芳基环; （E）杂环芳基（1-3C）烷基和其药学上可接受的盐，用于治疗神经精神障碍，如精神病; 包括化合物I或I'和药学上可接受的稀释剂或载体的制药组合物;以及治疗神经精神障碍的方法，包括向需要此类治疗的哺乳动物（包括人）施用公式I或I'的化合物或其药学上可接受的盐的有效量。本发明还涉及用于生产对映体甲基蒽醌亚砜的新工艺。
• Tricyclic antipsychotic compounds
  申请人：Zeneca Limited

  公开号：US05681840A1

  公开（公告）日：1997-10-28

  Compounds of formula I or I', ##STR1## wherein X and Y are independently selected from hydrogen, halo, and (1-6C)alkoxy; R.sup.1 is selected from (A) (1-6C)alkyl; (B) phenyl and naphthyl or substituted versions thereof; (C) phenyl(1-3C)alkyl and naphthyl(1-3C)alkyl; (D) five- and six-membered heteroaryl rings; (E) heteroaryl(1-3C)alkyl and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disorders such as psychoses; pharmaceutical compositions comprising a compound of formula I or I' and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropsychiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective amount of a compound of formula I or I', or a pharmaceutically acceptable salt thereof are claimed. The invention also relates to novel processes for producing enantiomeric methanoanthracenyl sulfoxides.

  公式I或I'的化合物，其中X和Y独立地选择氢，卤素和（1-6C）烷氧基; R1从以下选项中选择：（A）（1-6C）烷基; （B）苯基和萘基或其取代物; （C）苯基（1-3C）烷基和萘基（1-3C）烷基; （D）五元和六元杂环芳基环; （E）杂环芳基（1-3C）烷基及其药学上可接受的盐，用于治疗神经精神障碍，例如精神病; 包括公式I或I'的化合物和药学上可接受的稀释剂或载体的制药组合物;以及治疗神经精神障碍的方法，包括向需要此类治疗的哺乳动物（包括人）施用公式I或I'的化合物或其药学上可接受的盐的有效量。该发明还涉及用于生产对映体甲基蒽醌亚砜的新型工艺。
• Methanoanthracenes as dopamine antagonists
  申请人：ZENECA LIMITED

  公开号：EP0533344A1

  公开（公告）日：1993-03-24

  Compounds of formula I, and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disorders such as psychoses; pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropschiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.

  用于治疗神经精神疾病（如精神病）的式 I 化合物及其药学上可接受的盐；包含式 I 化合物和药学上可接受的稀释剂或载体的药物组合物；以及治疗神经精神疾病的方法，包括向需要此类治疗的哺乳动物（包括人）施用有效量的式 I 化合物或其药学上可接受的盐。